UA105645C2 - Method thrombosis ususe of dabigatran etexilate or a salt thereof for preventing stroke in patient suffering from atrial fibrillation
- Google Patents
Method thrombosis ususe of dabigatran etexilate or a salt thereof for preventing stroke in patient suffering from atrial fibrillation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорінгер Інгельхайм Інтернаціональ ГмбхfiledCriticalБьорінгер Інгельхайм Інтернаціональ Гмбх
Priority claimed from PCT/EP2009/064873external-prioritypatent/WO2010055021A1/en
Publication of UA105645C2publicationCriticalpatent/UA105645C2/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.
UAA201107207A2008-11-112009-11-10Method thrombosis ususe of dabigatran etexilate or a salt thereof for preventing stroke in patient suffering from atrial fibrillation
UA105645C2
(en)
Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
DIMALEATE OF 9- [4- (3-CHLORINE-2-FLUORO-PHENYLAMINE) -7-METOXI-QUINAZOLIN-6-ILOXI] -1,4-DIAZA-ESPIRO [5.5] UNDECAN-5-ONA, ITS USE AS A MEDICINAL PRODUCT AND HIS PREPARATION.
Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy